Next Article in Journal
Diagnostic and Prognostic Value of CEA and CA19-9 in Colorectal Cancer
Previous Article in Journal
Osteocalcin, Osteopontin and RUNX2 Expression in Patients’ Leucocytes with Arteriosclerosis
Review

Cardiotoxicity Associated with Anti-CD19 Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Recognition, Risk Factors, and Management

1
Houston Methodist Cancer Center, Houston Methodist Hospital, 6445 Main Street, Outpatient Center, 24th Floor, Houston, TX 77030, USA
2
Houston Methodist DeBakey Heart and Vascular Center, 6565 Fannin St, Houston, TX 77030, USA
3
Callahan Cancer Center, Great Plains Health, 601 W Leota St, North Platte, NE 69101, USA
*
Authors to whom correspondence should be addressed.
Academic Editor: Gaetano Santulli
Diseases 2021, 9(1), 20; https://doi.org/10.3390/diseases9010020
Received: 9 February 2021 / Revised: 4 March 2021 / Accepted: 15 March 2021 / Published: 17 March 2021
Chimeric antigen receptor T-cells (CAR-T) are improving outcomes in pediatric and adult patients with relapsed or refractory B-cell acute lymphoblastic leukemias and subtypes of non-Hodgkin Lymphoma. As this treatment is being increasingly utilized, a better understanding of the unique toxicities associated with this therapy is warranted. While there is growing knowledge on the diagnosis and treatment of cytokine release syndrome (CRS), relatively little is known about the associated cardiac events that occur with CRS that may result in prolonged length of hospital stay, admission to the intensive care unit for pressor support, or cardiac death. This review focuses on the various manifestations of cardiotoxicity, potential risk factors, real world and clinical trial data on prevalence of reported cardiotoxicity events, and treatment recommendations. View Full-Text
Keywords: CAR-T; cardiotoxicity; hypotension; heart failure; cytokine release syndrome; leukemia; lymphoma CAR-T; cardiotoxicity; hypotension; heart failure; cytokine release syndrome; leukemia; lymphoma
Show Figures

Figure 1

MDPI and ACS Style

Burns, E.A.; Gentille, C.; Trachtenberg, B.; Pingali, S.R.; Anand, K. Cardiotoxicity Associated with Anti-CD19 Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Recognition, Risk Factors, and Management. Diseases 2021, 9, 20. https://doi.org/10.3390/diseases9010020

AMA Style

Burns EA, Gentille C, Trachtenberg B, Pingali SR, Anand K. Cardiotoxicity Associated with Anti-CD19 Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Recognition, Risk Factors, and Management. Diseases. 2021; 9(1):20. https://doi.org/10.3390/diseases9010020

Chicago/Turabian Style

Burns, Ethan A., Cesar Gentille, Barry Trachtenberg, Sai R. Pingali, and Kartik Anand. 2021. "Cardiotoxicity Associated with Anti-CD19 Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Recognition, Risk Factors, and Management" Diseases 9, no. 1: 20. https://doi.org/10.3390/diseases9010020

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop